NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a cancer-testis antigen (CTA)
which is expressed in various tumors. In TCR-T therapy, researchers take the blood of a
certain patient, select T cells and insert genes into the cell that expressing a kind of
protein that targeting NY-ESO-1. The genetically engineered cells are called NY-ESO-1 TCR-T
cells. Then the engineered cells are re-infused to the cancer patients to cure the disease or
prolong life.
Phase:
Phase 1
Details
Lead Sponsor:
TCRCure Biopharma Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences